Review Article
Volume 16 Issue 3 - 2020
Bacterial Resistance; A Perspective on Beta-Lactamase Enzymes
Orole Olukayode Olugbenga*
Department of Microbiology, Federal University of Lafia, Nigeria
*Corresponding Author: Orole Olukayode Olugbenga, Department of Microbiology, Federal University of Lafia, Nigeria.
Received: November 11, 2019; Published: February 10, 2020


Bacteria with resistant genes are spreading fast, from place to place, and genes formerly encoded by the chromosome are now encoded by plasmids, and by lateral transfer can now jump from one bacteria species to a completely new species. Decade of treating bacteria and especially the resistant strains have not brought solace but fear and concern as newer super resistant bacteria are evolving without an equal treatment plan to counter them. Beta-lactamases with their prevalence and increasing types have been successful in raising a worthwhile defense mechanism in bacteria against beta-lactam antibiotics which is the most used group of antibiotics. As a result of the resistance build up to these antibiotics and cost of finding and producing new antibiotics, research has led to a means of overcoming the plague of resistance, hence the introduction of chemical compounds known as inhibitors. Inhibitors work on the premise that beta-lactamase messes up beta-lactam ring of the antibiotic, then the inhibitor messes up the beta-lactamase by deactivation in defense of the antibiotic. They are added to beta-lactam antibiotics to make them more efficient and effective. New antibiotics are seldom produced due to high cost involved, and the saving wall of inhibitors is continually breached by newer version of beta-lactamases. Problem resulting from this failure include increasing cost of treatment, mortalities, and community prone to bacterial resistant scourge. The review summarily highlight the strength of beta-lactamases over beta-lactam antibiotics, and called for pro-active measures to tackle the problem.

Keywords: Bacteria; Resistance; Plasmid; Beta-lactamase; Antibiotics


  1. Rice LB. “Mechanisms of Resistance and Clinical Relevance of Resistance to β-Lactams, Glycopeptides, and Fluoroquinolones”. Mayo Clinic Proceedings 87.2 (2012): 198-208.
  2. Pitout JDD., et al. “Molecular Characteristics of Extended-Spectrum-β-Lactamase-Producing Escherichia coli Isolates Causing Bacteremia in the Calgary Health Region from 2000 to 2007: Emergence of Clone ST131 as a Cause of Community-Acquired Infections”. Antimicrobial Agents and Chemotherapy 53.7 (2009): 2846-2851.
  3. Lau SH., et al. “UK epidemic Escherichia coli strains A-E, with CTX-M-15 beta-lactamase, all belong to the international O25: H4-ST131 clone”. Journal of Antimicrobial Chemotherapy 62 (2008): 1241-1244.
  4. Nicole-Chanoine MH., et al. “Intercontinental emergence of Escherichia coli clone O25: H4-ST131 producing CTX-M-15”. Journal of Antimicrobial Chemotherapy 61 (2008): 273-281.
  5. Amyes SGB Gemell CG. “Antibiotic resistance”. Journal of Medical Microbiology 46 (1997): 436-470.
  6. Medeiros AA. “Evolution and dissemination of β-lactamases accelerated by generations of β-lactam antibiotics”. Reviews of Infectious Diseases 24 (1997): S19-S45.
  7. Oboho KO. “Problems of Venereal Disease in Nigeria. 1. Gonococcal resistance to antibiotics and treatment of Gonorrhoea”. Family Practice 1.4 (1984): 219-21.
  8. Everaert A and Coenye T. “Effect of β-Lactamase inhibitors on In vitro activity of β-Lactam antibiotics against Burkholderia cepacia complex species”. Antimicrobial Resistance and Infection Control 5 (2016): 44
  9. French GL. “Clinical impact and relevance of antibiotic resistance”. Advanced Drug Delivery Reviews 57 (2005): 1514-27.
  10. McGowan Jr JE. “Economic impact of antimicrobial resistance”. Emerging Infectious Diseases Journal 7 (2001): 286-292.
  11. International Health Regulations. Alert, response, and capacity building under the International Health Regulations (IHR), 2nd Edition (2005): 74.
  12. Delcour AH. “Outer membrane permeability and antibiotic resistance”. Biochimica et Biophysica Acta 1794.5 (2009): 808-816.
  13. Martins A., et al. “Mechanisms of Resistance in Bacteria: An Evolutionary Approach”. The Open Microbiology Journal 7 (2013): 53-58.
  14. Billard-Pomares T., et al. “Complete nucleotide sequence of plasmid pTN48, encoding the CTX-M-14 extended-spectrum β-lactamase from an Escherichia coli O102-ST405 strain”. Antimicrobial Agents and Chemotherapy 55.3 (2011): 1270-1273.
  15. Fernandes R., et al. “β-Lactams: chemical structure, mode of action and mechanisms of resistance”. Reviews in Medical Microbiology 24.1 (2013): 7-17.
  16. Walsh C. “Antibiotics, action, origins and resistance”. Washington, District of Columbia: ASM Press (2003).
  17. Walsh C. “Molecular mechanisms that confer antibacterial drug resistance”. Nature 406 (2000): 775-781.
  18. Sanders CC and Sanders WE Jr. “β-Lactam resistance in Gram-negative bacteria: global trends and clinical impact”. Clinical Infectious Diseases 15 (1992): 824-839.
  19. Ghuysen JM. “Serine β-lactamases and penicillin-binding proteins”. Annual Review of Microbiology 45 (1991): 37-67.
  20. Therrien C and Levesque RC. “Molecular basis of antibiotic resistance and β-lactamase inhibition by mechanism-based inactivators: perspectives and future directions”. FEMS Microbiology Reviews 24.3 (2000): 251-262.
  21. Hauser AR. “Antibiotic Basics for Clinicians. The ABCs of Choosing the Right Antibacterial Agent”. 2nd Edition. Lippincott Williams & Wilkins (2013).
  22. Fritsche TR., et al. “Antimicrobial activity of ceftobiprole, a novel antimethicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006)”. Diagnostic Microbiology and Infectious Disease 61 (2008): 86-95.
  23. Edwards JR and Betts MJ. “Carbapenems: the pinnacle of the beta-lactam antibiotics or room for improvement?”. The Journal of Antimicrobial Chemotherapy 45 (2000): 1-4.
  24. Martinez JL. “The role of natural environments in the evolution of resistance traits in pathogenic bacteria”. Proceedings of the Royal Society 276 (2009): 2521-2530. 
  25. Livermore DM and Woodford N. “Carbapenemases: a problem in waiting?”. Current Opinion in Microbiology 3 (2000): 489-495.
  26. Drawz SM and Bonomo RA. “Three Decades of β-Lactamase Inhibitors”. Clinical Microbiology Reviews 23.1 (2010): 160-201. 
  27. Wang L and Archer GL. “Roles of CcrA and CcrB in excision and integration of staphylococcal cassette chromosome mec, a Staphylococcus aureus genomic island”. Journal of Bacteriology 192.12 (2010): 3204-3212.
  28. Deurenberg RH and Stobberingh EE. “The evolution of Staphylococcus aureus”. Infection, Genetics and Evolution 8.6 (2008): 747-763.
  29. Coffey TJ., et al. “Horizontal transfer of multiple penicillin-binding protein genes, and capsular biosynthetic genes, in natural populations of Streptococcus pneumoniae”. Molecular Microbiology 5.9 (1991): 2255-2260. 
  30. Spratt BG. “Hybrid penicillin-binding proteins in penicillin-resistant strains of Neisseria gonorrhoeae”. Nature 332 (1988): 173-176.
  31. Jacoby G.A and Medeiros AA. “More extended-spectrum β-lactamases”. Antimicrobial Agents and Chemotherapy 35.9 (1991): 1697-1704.
  32. Queenan AM and Bush K. “Carbapenemases: the versatile beta-lactamases”. Clinical Microbiology Reviews 20.3 (2007): 440-458.
  33. Tzouvelekis LS., et al. “CTX-M-type beta-lactamases: an emerging group of extended-spectrum enzymes”. International Journal of Antimicrobial Agents 14.2 (2000): 137-142.
  34. Sagar A., et al. “Search for non-lactam inhibitors of mtb β-lactamase led to its open shape in apo state: new concept for antibiotic design”. Scientific Reports 7 (2017).
  35. Chambers HF. et al. “Can penicillins and other beta-lactam antibiotics be used to treat tuberculosis?”. Antimicrobial Agents and Chemotherapy 39 (1995): 2620-2624.
  36. Finch R. “Beta-lactam antibiotics and mycobacteria”. The Journal of Antimicrobial Chemotherapy 18 (1986): 6-8.
  37. Bradford PA. “Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat”. Clinical Microbiology Reviews 14 (2001): 933-951.
  38. Hugonnet JE and Blanchard JS. “Irreversible inhibition of the Mycobacterium tuberculosis beta-lactamase by clavulanate”. Biochemistry 46 (2007): 11998-12004.
  39. Wang F., et al. “Crystal structure and activity studies of the Mycobacterium tuberculosis beta-lactamase reveal its critical role in resistance to beta-lactam antibiotics”. Antimicrobial Agents and Chemotherapy 50 (2006): 2762-2771.
  40. Zeng X and Lin J. “Beta-lactamase induction and cell wall metabolism in Gram-negative bacteria”. Frontiers in Microbiology 4 (2013): 128. 
  41. Bush K., et al. “A functional classification scheme for β-lactamases and its correlation with molecular structure”. Antimicrobial Agents and Chemotherapy 39 (1995): 1211-1233.
  42. Kumarasamy KK., et al. “Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study”. The Lancet Infectious Diseases 10 (2010): 597-602. 
  43. Bush K. “Metallo-beta-lactamases: a class apart”. Clinical Infectious Diseases 27 (1998): S48-S53.
  44. Hinchliffe P., et al. “Cross-class metallo-β-lactamase inhibition by bisthiazolidines reveals multiple binding modes”. 113.26 (2016): E3745-E3754.
  45. Xu D., et al. “Catalytic Mechanism of Class B2 Metallo-β-lactamase”. The Journal of Biological Chemistry 281 (2006): 8740-8747.
  46. Nazik H., et al. “Carbapenem resistance due to blaOXA-48 among ESBL-producing Escherichia coli and Klebsiella pneumoniae isolates in a University hospital, Turkey”. The Southeast Asian Journal of Tropical Medicine and Public Health 43 (2012): 1178-1185.
  47. Watkins RR., et al. “Novel β-lactamase inhibitors: a therapeutic hope against the scourge of multidrug resistance”. Frontiers in Microbiology 4 (2013): 392.
  48. Sims SV., et al. “Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor”. Clinical Pharmacist 9.5 (2017).
  49. Lakshmi PTV., et al. “Reduction of Silver Ions by Cell Free Extracts of Westiellopsis sp.,” International Journal of Biomaterials (2015). 
  50. Helfand MS., et al. “Understanding Resistance to β-Lactams and β-Lactamase Inhibitors in the SHV β-Lactamase: Lessons from the mutagenesis of Ser-130”. The Journal of Biological Chemistry 278 (2003): 52724-52729.
  51. Helfand MS., et al. “Unexpected advanced generation cephalosporinase activity”. The Journal of Biological Chemistry 277 (2002): 47719-47723 
  52. Hujer AM., et al. “Mutagenesis of amino acid residues in the SHV-1 beta-lactamase: the premier role of Gly238Ser in penicillin and cephalosporin resistance”. Biochimica et Biophysica Acta 1547 (2001): 37-50.
  53. Vakulenko SB., et al. “Selection and characterization of beta-lactam-beta-lactamase inactivator-resistant mutants following PCR mutagenesis of the TEM-1 beta-lactamase gene”. Antimicrobial Agents and Chemotherapy 42 (1998): 1542-1548.
  54. Ripoll A., et al. “In vitro selection of variants resistant to β-lactams plus β-lactamase inhibitors in CTX-M β-lactamases: predicting the in vivo scenario?”. Antimicrobial agents and Chemotherapy 55.10 (2011): 4530-4536.
  55. Thomas VL., et al. “Structural consequences of the inhibitor-resistant Ser130Gly substitution in TEM β-lactamase”. Biochemistry 44.26 (2005): 9330-9338.
  56. Sun T., et al. “Inhibitor-resistant class A β-lactamases: consequences of the Ser130-to-Gly mutation seen in Apo and tazobactam structures of the SHV-1 variant”. Biochemistry 43.44 (2004): 14111-14117.
  57. Aumeran C., et al. “Effects of Ser130Gly and Asp240Lys substitutions in extended-spectrum β-lactamase CTX-M-9”. Antimicrobial agents and Chemotherapy 47.9 (2003): 2958-2961.
  58. Meroueh SO., et al. “Molecular Dynamics at the Root of Expansion of Function in the M69L Inhibitor-Resistant TEM β-Lactamase from Escherichia coli”. Journal of the American Chemical Society 124 (2002): 9422-9430.
  59. Lagace-Wiens P., et al. “Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections”. Core Evidence 9 (2014): 13-25.
  60. Drawz SM., et al. “New beta-lactamase inhibitors: a therapeutic renaissance in an MDR world”. Antimicrobial Agents and Chemotherapy 58 (2014): 1835-1846.
  61. World Health Organization. Antimicrobial resistance: global report on surveillance, Geneva (2017). 
  62. Ruppe E., et al. “Carriage of CTX-M-15 - producing Escherichia coli among remote-living children in Senegal”. Antimicrobial Agents and Chemotherapy 53 (2009): 3135-3137
  63. Teillant A., et al. “Potential burden of antibiotic resistance on surgery and cancer chemotherapy antibiotic prophylaxis in the USA: a literature review and modeling study”. Lancet Infectious Disease (2015).
  64. Liu Z., et al. “Identification and characterization of the first Escherichia coli strain carrying NDM-1 gene in China”. PLoS One 8 (2013): e66666.
  65. Kellermayer R. "Prospects and challenges for intestinal microbiome therapy in pediatric gastrointestinal disorders". World Journal of Gastrointestinal Pathophysiology 4.4 (2013): 91-93.
  66. Pournaras, S., et al. “Detection of the new metallo-β-lactamase VIM-19 along with KPC-2, CMY-2 and CTX-M-15 in Klebsiella pneumoniae”. Journal of Antimicrobial Chemotherapy 65 (2010): 1604-1607. 
  67. Johnson JR., et al. “Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States”. Clinical Infectious Diseases 51.3 (2010): 286-294.
  68. Kim J., et al. “Risk factors of community- onset spontaneous bacterial peritonitis caused byfluoroquinolone-resistant Escherichia coli in patients with cirrhosis”. Liver International 34 (2014): 695-699.
  69. Nutman A., et al. “A case control study to identify predictors of 14-day mortality following carbapenem-resistant Acinetobacter baumannii bacteraemia”. Clinical Microbiology and Infection 20 (2014): 1028-1034.
  70. Unemo M and Shafer WM. “Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future”. Clinical Microbiology Review 27 (2014): 587-613.
  71. Cosgrove SE., et al. “Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis”. Clinical Infectious Disease 36 (2013): 3-9.
  72. Wagenlehner FME., et al. “Infective complications after prostate biopsy: outcome of the Global Prevalence Study of Infections in Urology (GPIU)”. European Urology 63 (2013): 521-527.
  73. Borer A., et al. “Attributable mortality rate for carbapenem-resistant Klebsiella pneumonia bacteremia”. Infectious Control Hospital Epidemiology 30 (2009): 972-976.
  74. Melzer M and Petersen I. “Mortality following bacteraemic infection caused by extended spectrum β-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli”. Journal of Infection 55 (2007): 254-259. 
  75. Centers for Disease Control and Prevention (CDC). Antibiotic resistance threats in the United States, 2013. Atlanta: CDC (2013). 
  76. Suzuki S., et al. “Change in the prevalence of extended-spectrum-beta-lactamase-producing Escherichia coli in Japan by clonal spread”. Journal of Antimicrobial Chemotherapy 63 (2009): 72-79.
  77. Literacka E., et al. “blaCTX-M genes in Escherichia coli strains from Croatian hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a, blaCTX-M-15) genetic structures”. Antimicrobial Agents and Chemotherapy 53 (2009): 1630-1635.
Citation: Orole Olukayode Olugbenga. “Bacterial Resistance; A Perspective on Beta-Lactamase Enzymes". EC Microbiology 16.3 (2020): 01-12.

PubMed Indexed Article

EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005

EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777

EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347

EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478

EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253

EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033

EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992

EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505

EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793

EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211

EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047

EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560

EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318

EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819

EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840

EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344

EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476

EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658

EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489

EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278

EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108

EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571

EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333

EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883

EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001

EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937

EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723

EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726

EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603

EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646

EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616

EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290

EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226

EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812

EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268

News and Events

August Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the August issue of respective journals and can be viewed in the current issue pages.

Submission Deadline for September Issue

Ecronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the September issue of respective journals. Submissions are accepted on/before August 15, 2020.

Certificate of Publication

Ecronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

Ecronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.

Immediate Assistance

The prime motto of this team is to clarify all the queries without any delay or hesitation to avoid the inconvenience. For immediate assistance on your queries please don't hesitate to drop an email to